沐舒坦防治早产儿呼吸窘迫综合征的临床研究

Clinical research of Mucosolvan in the prevention and treatment of premature infants with respiratory distress syndrome

目的探讨沐舒坦对早产儿呼吸窘迫综合征(NRDS)的预防和治疗作用。方法将130例早产儿随机分组,观察组67例应用沐舒坦30mg/(kg·d),4次/d。对照组63例常规治疗,观察两组NRDS发生率,以及死亡率。结果治疗组NRDS发生率和死亡率均低于对照组,两组比较差异具有显著性(P<0.01)。结论沐舒坦对早产儿呼吸窘迫综合征有一定的预防和治疗作用。

Objective To investigate the role of Mucosolvan in the prevention and treatment of premature infants with respiratory distress syndrome （NRDS）. Methods 130 cases of premature infants were randomized into two groups. The experimental groups of 67 cases were given Mucosolvan 30 mg/（kg.d）, 4 times/d. Control group of 63 cases received conventional treatment. Incidences of NRDS as well as mortality rates were observed. Results NRDS incidence and mortality rates of experimental group are lower than the control group, and the difference between the two groups has statistical significance （P〈0.01）. Conclusion Mucosolvan have a certain role in the prevention and treatment of premature infants with respiratory distress syndrome.